Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: A need for higher doses in diabetic patients?

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2454-2461

  Hollenberg, Norman K ^a   Fisher, Naomi D L ^a   Nussberger, Juerg ^b   Moukarbel, George V ^a   Barkoudah, Ebrahim ^a   Danser, A H Jan ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic kidney disease; juxtaglomerular cell; prorenin; renin angiotensin system

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; CAPTOPRIL; IRBESARTAN; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; FEMALE; GLOMERULUS FILTRATION RATE; HIGH SALT DIET; HUMAN; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 81355127389     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834c627a     Document Type: Article

References (34)

1. Price DA, Porter LE, Gordon M, Fisher NDL, De'Oliveira JM, Laffel LM, et al. The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc Nephrol 1999; 10:2382-2391.
2. Lansang MC, Price DA, Laffel LM, Osei SY, Fisher NDL, Erani D, Hollenberg NK. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59:1432-1438.
3. De'Oliveira JM, Price DA, Fisher NDL, Allan DR, McKnight JA, Williams GH, Hollenberg NK. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52:771-777.
4. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63:172-178.
5. Danser AHJ, Derkx FHM, Schalekamp MADH, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J. Hypertens 1998; 16:853-862.
6. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J. 2011; 32:2135-2142.
7. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J. Med 1991; 324:1098-1104.
8. Azizi M, Bissery A, Lamarre-Cliche M, Mé nard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004; 43:785-790.
9. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J. Med 1985; 312:1412-1417.
10. Deinum J, Ronn B, Mathiesen E, Derkx FHM, Hop WC, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42:1006-1010.
11. Danser AHJ, van den Dorpel MA, Deinum J, Derkx FHM, Franken AAM, Peperkamp E, et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J. Clin Endocrinol Metab 1989; 68:160-167.
12. Fisher NDL, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
13. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32:387-392.
14. Price DA, Fisher NDL, Lansang MC, Stevanovic R, Williams GH, Hollenberg NK. Renal perfusion in blacks: Alterations caused by insuppressibility of intrarenal renin with salt. Hypertension 2002; 40:186-189.
15. Nasjletti A, Colina-Chourio J, McGiff JC. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 1975; 37:59-65.
16. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 1994; 23:44-51.
17. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52:1076-1083.
18. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, Nguyen G, Danser AH. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-1157.
19. Schuijt MP, Basdew M, van Veghel R, de Vries R, Saxena PR, Schoemaker RG, Danser AHJ. AT2 receptor-mediated vasodilation in the heart: effect of myocardial infarction. Am. J. Physiol 2001; 281:H2590-H2596.
20. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J. Clin Invest 1997; 100:264-269.
21. van Esch JHM, Schuijt MP, Sayed J, Choudry Y, Walther T, Danser AHJ. AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. Br J. Pharmacol 2006; 148:452-458.
22. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial. Diabetologia 2010; 53:1576-1580.
23. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness. Am. J. Hypertens 2007; 20:587-597.
24. Danser AHJ, Charney A, Feldman DL, Nussberger J, Fisher N, Hollenberg N. The renin rise with aliskiren: It's simply stoichiometry. Hypertension 2008; 51:e27-e28.
25. Schalekamp MADH, Derkx FHM, Deinum J, Danser AHJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J. Hypertens 2008; 26:928-937.
26. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AHJ. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: Therapeutic consequences? Eur Heart J. 2009; 30:805-812.
27. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32:1873-1879.
28. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J. Med 2008; 358:2433-2446.
29. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003; 26:2268-2274.
30. Schalekamp MADH, Danser AHJ. Angiotensin II production and distribution in the kidney. I. A kinetic model. Kidney Int 2006; 69:1543-1552.
31. Schalekamp MADH, Danser AHJ. Angiotensin II production and distribution in the kidney. II. Model-based analysis of experimental data. Kidney Int 2006; 69:1553-1557.
32. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39:316-322.
33. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé C, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J. Hypertens 2007; 25:2441-2453.
34. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009; 24:1663-1671